IDEAYA Biosciences ($IDYA) has become a catalyst-driven trade into the randomized Phase 2/3 OptimUM-02 topline PFS readout for darovasertib + crizotinib in 1L HLA-A2-negative metastatic uveal melanoma, expected late March 2026. Investors are framing the event as a binary validation of the single-arm survival signal and, more broadly, as proof that PKC inhibition plus cMET blockade can meaningfully shift frontline outcomes in a historically refractory disease. The stock only structurally re-rates if the dataset shows clear and clinically meaningful PFS separation versus investigator’s choice, with a persuasive hazard ratio and clean safety profile that supports regulatory positioning for accelerated approval. Investors will overweight absolute median PFS delta versus control, hazard ratio stability across key baseline characteristics, event maturity, and whether discontinuation rates or dose reductions erode real-world combinability. If the PFS delta compresses toward historical controls or toxicity complicates exposure, the narrative shifts from “first targeted backbone in UM” to “single-arm inflation,” compressing franchise expectations and pushing valuation back toward longer-duration optionality in DLL3 and MTAP programs. Options are pricing +/- 90% volatility.
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.
🚨 ALERT: Darovasertib + Crizotinib Phase 2/3 PFS Readout (Q1 2026)
📅 TIMING: Q12026
📈 IMPLIED MOVE: ~±90%
BACKGROUND:
